Clinical Trial Update: Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy [Phase 4]

View source ↗

Summary

Phase 4 trial update on ferric carboxymaltose for treating iron-deficiency anemia in cancer patients with multiple myeloma on chemotherapy; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia
• Multiple Myeloma

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: Vifor Pharma | Conditions: Iron-Deficiency Anemia | Phase 4 | Status: TERMINATED